Tramadol potentiates chemotherapy efficacy in hepatocellular carcinoma cells
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths, leading to poor responses to chemotherapy. Cancer-related pain affects up to 90% of these patients, significantly impairing their quality of life. Tramadol, a prescribed analgesic for cancer pain, has shown anti-tumour effects in various malignancies, yet its potential in HCC remains largely unexplored. In this study, we investigated tramadol's anti-proliferative, pro-apoptotic, and autophagy-inducing effects in HepG2, Hep3B, and Huh7 cell lines. Tramadol significantly inhibits cell proliferation in a dose-dependent manner, leading to a reduction in the S-phase and subG1 phase accumulation. It induces apoptosis in HepG2 and Hep3B, increases late apoptosis/necrosis, and enhances autophagy. Additionally, tramadol increased the cytotoxicity of cisplatin and 5-fluorouracil, with significant reductions in their IC50 values. Overall, tramadol inhibits HCC growth, promotes apoptosis, and enhances chemotherapy efficacy, suggesting it could be a dual-benefit therapeutic strategy for HCC.
Authors
- Zih-Syuan Wu (ORCID: https://orcid.org/0000-0003-3342-4195)
- Shuting Liu (ORCID: https://orcid.org/0000-0001-7581-1498)
- Hsiu‐Lung Fan
- Yi‐Hsuan Huang (ORCID: https://orcid.org/0000-0003-3350-6879)
- Zhi-Fu Wu
- Teng-Wei Chen
- Shih-Ming Huang
Institutions
- Tri-Service General Hospital (TW)
- Kaohsiung Medical University (TW)
- Wan Fang Hospital (TW)
- National Defense Medical Center (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Journal of Enzyme Inhibition and Medicinal Chemistry
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1080/14756366.2026.2755636
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00